Literature DB >> 21704011

Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline.

Rodrigo Medeiros1, Masashi Kitazawa, Antonella Caccamo, David Baglietto-Vargas, Tatiana Estrada-Hernandez, David H Cribbs, Avraham Fisher, Frank M LaFerla.   

Abstract

Alzheimer's disease (AD) is pathologically characterized by tau-laden neurofibrillary tangles and β-amyloid deposits. Dysregulation of cholinergic neurotransmission has been implicated in AD pathogenesis, contributing to the associated memory impairments; yet, the exact mechanisms remain to be defined. Activating the muscarinic acetylcholine M(1) receptors (M(1)Rs) reduces AD-like pathological features and enhances cognition in AD transgenic models. To elucidate the molecular mechanisms by which M(1)Rs affect AD pathophysiological features, we crossed the 3xTgAD and transgenic mice expressing human Swedish, Dutch, and Iowa triple-mutant amyloid precursor protein (Tg-SwDI), two widely used animal models, with the M(1)R(-/-) mice. Our data show that M(1)R deletion in the 3xTgAD and Tg-SwDI mice exacerbates the cognitive impairment through mechanisms dependent on the transcriptional dysregulation of genes required for memory and through acceleration of AD-related synaptotoxicity. Ablating the M(1)R increased plaque and tangle levels in the brains of 3xTgAD mice and elevated cerebrovascular deposition of fibrillar Aβ in Tg-SwDI mice. Notably, tau hyperphosphorylation and potentiation of amyloidogenic processing in the mice with AD lacking M(1)R were attributed to changes in the glycogen synthase kinase 3β and protein kinase C activities. Finally, deleting the M(1)R increased the astrocytic and microglial response associated with Aβ plaques. Our data highlight the significant role that disrupting the M(1)R plays in exacerbating AD-related cognitive decline and pathological features and provide critical preclinical evidence to justify further development and evaluation of selective M(1)R agonists for treating AD.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21704011      PMCID: PMC3157199          DOI: 10.1016/j.ajpath.2011.04.041

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

1.  Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation.

Authors:  L Lin; B Georgievska; A Mattsson; O Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

Review 2.  Memory formation and the regulation of gene expression.

Authors:  O Stork; H Welzl
Journal:  Cell Mol Life Sci       Date:  1999-04       Impact factor: 9.261

Review 3.  Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies.

Authors:  D D Flynn; G Ferrari-DiLeo; A I Levey; D C Mash
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

4.  Cerebral amyloid angiopathy: amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease.

Authors:  R O Weller; A Massey; T A Newman; M Hutchings; Y M Kuo; A E Roher
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

5.  Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice.

Authors:  S E Hamilton; M D Loose; M Qi; A I Levey; B Hille; G S McKnight; R L Idzerda; N M Nathanson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 6.  Activation of immediate early genes and memory formation.

Authors:  W Tischmeyer; R Grimm
Journal:  Cell Mol Life Sci       Date:  1999-04       Impact factor: 9.261

Review 7.  Biochemical dysfunction and memory loss: the case of Alzheimer's dementia.

Authors:  E von Linstow Roloff; B Platt
Journal:  Cell Mol Life Sci       Date:  1999-04       Impact factor: 9.261

Review 8.  CREB: a message to remember.

Authors:  R Lamprecht
Journal:  Cell Mol Life Sci       Date:  1999-04       Impact factor: 9.261

9.  M1 receptors play a central role in modulating AD-like pathology in transgenic mice.

Authors:  Antonella Caccamo; Salvatore Oddo; Lauren M Billings; Kim N Green; Hilda Martinez-Coria; Abraham Fisher; Frank M LaFerla
Journal:  Neuron       Date:  2006-03-02       Impact factor: 17.173

10.  Spatial memory in aged rats is related to PKCgamma-dependent G-protein coupling of the M1 receptor.

Authors:  M A Rossi; D C Mash; L deToledo-Morrell
Journal:  Neurobiol Aging       Date:  2005-01       Impact factor: 4.673

View more
  39 in total

1.  Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer's disease.

Authors:  Yash B Joshi; Jin Chu; Domenico Praticò
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Chronic Administration of Scopolamine Increased GSK3βP9, Beta Secretase, Amyloid Beta, and Oxidative Stress in the Hippocampus of Wistar Rats.

Authors:  Maricarmen Hernández-Rodríguez; Ivonne Maciel Arciniega-Martínez; Iohanan Daniel García-Marín; José Correa-Basurto; Martha Cecilia Rosales-Hernández
Journal:  Mol Neurobiol       Date:  2020-07-07       Impact factor: 5.590

Review 3.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 4.  Muscarinic acetylcholine receptors: novel opportunities for drug development.

Authors:  Andrew C Kruse; Brian K Kobilka; Dinesh Gautam; Patrick M Sexton; Arthur Christopoulos; Jürgen Wess
Journal:  Nat Rev Drug Discov       Date:  2014-06-06       Impact factor: 84.694

5.  Direct excitation of parvalbumin-positive interneurons by M1 muscarinic acetylcholine receptors: roles in cellular excitability, inhibitory transmission and cognition.

Authors:  Feng Yi; Jackson Ball; Kurt E Stoll; Vaishali C Satpute; Samantha M Mitchell; Jordan L Pauli; Benjamin B Holloway; April D Johnston; Neil M Nathanson; Karl Deisseroth; David J Gerber; Susumu Tonegawa; J Josh Lawrence
Journal:  J Physiol       Date:  2014-05-30       Impact factor: 5.182

Review 6.  Physiological roles of CNS muscarinic receptors gained from knockout mice.

Authors:  Morgane Thomsen; Gunnar Sørensen; Ditte Dencker
Journal:  Neuropharmacology       Date:  2017-09-11       Impact factor: 5.250

Review 7.  Therapeutics of Neurotransmitters in Alzheimer's Disease.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 8.  Alzheimer's Disease Therapeutic Approaches.

Authors:  Maria Revi
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  BMP9 ameliorates amyloidosis and the cholinergic defect in a mouse model of Alzheimer's disease.

Authors:  Rebecca M Burke; Timothy A Norman; Tarik F Haydar; Barbara E Slack; Susan E Leeman; Jan Krzysztof Blusztajn; Tiffany J Mellott
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

10.  Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.

Authors:  David Baglietto-Vargas; Rodrigo Medeiros; Hilda Martinez-Coria; Frank M LaFerla; Kim N Green
Journal:  Biol Psychiatry       Date:  2013-01-08       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.